Pfizer - and the failed M&A deal due to regulatory changes, a case study
STG CORPORATE AND COMMERCIAL LAW • CLIENT INSIGHT
The $160 billion deal the government killed
Pfizer, Allergan, and the Treasury rule that ended the largest pharmaceutical merger in history — what it teaches every dealmaker about regulatory risk, break fees, and the contract language that determines who wins when a transaction falls apart
By Katarina Strandberg | STG Corporate and Commercial Law AB
On the morning of 6 April 2016, the US Department of the Treasury published new regulations targeting a specific type of corporate transaction known as a tax inversion. The rules were issued without prior warning. They were made effective immediately. And they were drafted with unusual precision to address the exact structure of a deal that had been announced five months earlier and was forty-eight hours from closing.
That deal was the proposed merger of Pfizer and Allergan — the largest pharmaceutical transaction ever agreed, valued at approximately USD 160 billion. By the following morning the deal was dead. Pfizer paid a USD 400 million break fee and walked away. The government had not filed an injunction or found a legal violation. It had simply changed the rules — prospectively and immediately — in a way that made the transaction structurally pointless.
The story contains three distinct legal lessons that apply well beyond pharmaceutical M&A: what regulatory risk in a transaction actually means and how to price it, how the break fee mechanism is supposed to work and why it worked correctly here, and what buyers and sellers need to negotiate in the merger agreement itself to protect their position when the landscape shifts between signing and closing.
"The government did not stop a legal deal. It changed the economics so dramatically that the buyer chose not to proceed. The distinction matters enormously."
What Pfizer was trying to do — and why
Tax inversion is a structure in which an acquirer merges with a foreign company and re-incorporates the combined entity in the foreign jurisdiction, reducing the tax burden on the group's non-domestic income. The economic substance of the business remains primarily in the acquirer's home country. What changes is the legal address — and with it, the applicable tax rate.
Pfizer's motivation was straightforward. The US federal corporate tax rate in 2016 was 35%. Ireland's standard rate was 12.5%. Allergan, a pharmaceutical company incorporated in Ireland and headquartered in Dublin — best known for Botox — was the ideal vehicle. Pfizer held approximately USD 74 billion in offshore cash it could not repatriate without incurring significant US tax liability. Management estimated the combined structure would save approximately USD 1 billion per year in taxes. Over a decade, that is USD 10 billion. The strategic rationale for combining two significant pharmaceutical portfolios was genuine. But the tax saving was the deal's economic engine.
The transaction was structured as a reverse merger: technically Allergan acquired Pfizer, because Allergan as the Irish entity was the surviving legal person. In economic reality Pfizer's shareholders would own approximately 56% of the combined group. The structure had been carefully designed — with extensive tax and legal advice — to satisfy the existing inversion rules. Under those rules, a merger qualified for favourable treatment if the foreign company's shareholders ended up owning more than 40% of the combined entity. Allergan's shareholders would own approximately 44%. The transaction was, on its own terms, legal.
What Happened — From Announcement to Termination
Date
What happened
Nov 2015 - Pfizer and Allergan announce merger
USD 160 billion — approximately USD 363 per Allergan share. Allergan is the surviving legal entity (reverse merger), giving the combined company Irish tax domicile. Pfizer shareholders will own approximately 56% of the combined group.
6 Apr 2016
US Treasury issues TD 9761
New regulations issued without warning, effective immediately. Targeted specifically at serial acquisition techniques used to inflate foreign shareholder base for inversion threshold purposes. The Pfizer-Allergan structure falls below the new 60% qualifying threshold that is implemented.
6 Apr 2016 - Pfizer terminates
Pfizer xercises contractual termination right triggered by change in law and pays Allergan a sum of USD 400 million in reverse termination fee. Meaning that the deal died within 24 hours of the Treasury announcement.
May 2020 - Allergan acquired by AbbVie
For approximately USD 63 billion — a fraction of the Pfizer price, reflecting Allergan's standalone value rather than its value as a tax-efficient inversion vehicle.
What the Treasury did
The Treasury regulations published on 6 April 2016 targeted the specific technique Allergan had used in the years before the merger: a series of acquisitions of US companies that had inflated the size of Allergan's shareholder base — and therefore its apparent weight in the combined entity — for the purpose of satisfying the 60% threshold. The new rules said, in effect, that the authorities disregarded those acquisitions when calculating the ownership percentage. When they looked through them, the qualifying threshold was not met and the structure was deemed as an inversion subject to punitive tax treatment.
The rules were applied to transactions that had not yet closed. They did not undo completed deals or impose liability for past conduct. They changed the rules going forward, as of the date of publication. Critics argued that issuing regulations specifically to kill a legal transaction that was forty-eight hours from closing was an extraordinary use of executive regulatory authority — the kind of thing that should require legislation, not administrative action. The Treasury's response was that it had been publicly signalling its intention to act for years and that the purpose of the rules was defensible.
Regardless of the political angel, the Treasury did act within its statutory authority under the tax code and the regulations were valid. Pfizer had no legal right to request that they complete the transaction under the previous tax rulews. There is no general principle in US administrative law — or in most legal systems — that a transaction in progress is insulated from regulatory change that occur after signing.
"A legal opinion confirming that your deal is lawful today does not protect you against future government changes to the rules."
The break fee of USD 400 million
The Pfizer-Allergan merger agreement contained a reverse termination fee of USD 400 million payable by Pfizer in defined circumstances. One of those circumstances was a change in law or regulation that made consummation of the transaction commercially impracticable. The Treasury regulations qualified so Pfizer exercised the right, paid the fee, and the deal ended without closing and without litigation.
This is the break fee mechanism working exactly as designed. The fee compensated Allergan for the real costs of a failed transaction — management time, legal and advisory fees, the reputational and operational disruption of an announced deal that collapsed, and the foregone alternatives that Allergan had set aside while the merger was pending. It also priced the option to walk: Pfizer had agreed, at signing, that in certain defined circumstances it could exit at this cost such as new regulation impacting the core of the deal.
In the LVMH-Tiffany dispute, LVMH attempted to exit on grounds that were not clearly covered by the available termination mechanisms, generating months of litigation, a USD 425 million settlement and even more importantly; HVHM needed to move forward and buy Tiffany. In the Twitter-Musk dispute, the contractual termination right Musk sought to invoke was not available in the circumstances, and he was ultimately compelled to complete the deal at full price.
"The break fee is not a sign of bad faith. It is the pre-agreed price for a defined exit right."
The broader lesson about regulatory risk
Most M&A due diligence is focused on the target: its revenues, its contracts, its people, its litigation exposure. Significantly less attention is typically directed to the regulatory framework within which the transaction itself operates — and specifically to the risk that this framework changes between signing and closing in a way that hurts the target company or the deal structure in itself.
That risk is highest where the deal or the target comany operations is specifically motivated by a regulatory advantage. Pfizer's deal was motivated substantially by a tax. The deal's entire financial model depended on those rules remaining in place for the five or six months between announcement and closing — a period during which an administration that had publicly and repeatedly stated its intention to act against inversions was watching the largest inversion attempt in pharmaceutical history proceed toward completion.
STG — two questions every deal team should ask
What does the break fee actually cover, and in precisely what circumstances is it the buyer's exit? The break fee is only available in defined circumstances. Outside those circumstances — as Musk discovered with Twitter and LVMH discovered with Tiffany — the buyer may face compelled completion.
Does the deal survive a stress test that removes its primary regulatory or financial advantage? Before signing, the transaction should be valued under the assumption that the regulatory advantage underpinning it is unavailable. If the deal does not work on that basis, the price must reflect the risk that the advantage disappears — or the deal should not proceed without explicit contractual protection against that scenario.
How to Think About This From Both Sides of the Table
If you are the buyer
Map the MAE carve-outs to your worst-case scenarios before signing — each excluded category is a risk you have agreed to absorb
Understand when your break fee is a true exit right versus when specific performance (and hell-or-high-water clauses) leaves you exposed to compelled completion
Assess the political and regulatory environment if relevant and stress-teat the deal value against this basis
Ensure force majeure language is specific — generic boilerplate will not protect you against government-mandated delays
If you are the seller
Push for specific performance rights / hell-or-high-water clauses that operate across as many termination scenarios as possible
Narrow the conditions on which specific performance can not be exercised — a buyer should not be able to manufacture a termination condition
Size the reverse termination fee to reflect the genuine cost of an abandoned deal, not just a symbolic payment
Ensure the MAC definition does not give the buyer discretion over what qualifies — contested definitions create leverage in the wrong direction
Know your specific performance rights and be prepared to exercise them immediately if the buyer attempts an unwarranted exit
Regulatory risk in M&A transactions — whether arising from tax law, competition clearance, sector-specific regulation, or geopolitical developments — requires legal advice that looks beyond the current framework to realistic scenarios. The contract language that addresses those scenarios must be negotiated at signing, before the risk materialises. After the regulatory event, the parties are working with whatever the agreement says. There is no opportunity to revise it.
Advising on an acquisition or major commercial transaction with regulatory exposure?
Contact Kat Strandberg
STG Corporate and Commercial Law AB
This article is written for general informational purposes and does not constitute legal advice. All references to the Pfizer-Allergan transaction are based on publicly available information including SEC filings, US Treasury press releases and technical explanations, and contemporaneous financial press reporting. For advice on your specific transaction, please contact STG Corporate and Commercial Law AB directly.